Tarsus Q4 XDEMVY sales $13.1M; positive Phase 2a rosacea data

Tarsus Pharmaceuticals, Inc.

2023-FY EPS reported -$4.62 revenue$17,447,000

XDEMVY net product sales $13.1M in Q4, $14.7M total since late-August launch; >17,400 bottles dispensed.
Positive Phase 2a Galatea trial for TP-04 in papulopustular rosacea: statistically significant improvements in lesions and IGA score vs vehicle at Week 12.
Q4 net loss $41.9M ($1.31 EPS); full-year net loss $135.9M ($4.62 EPS).
Cash, equivalents and marketable securities $227.4M as of Dec 31, 2023.
~6,000 ECPs have started patients on XDEMVY; >50% prescribed to multiple patients as of Feb 23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Tarsus Pharmaceuticals, Inc. reported Full Year 2023 results: revenue $17.4 million.

Period: Full Year 2023
Revenue: $17.4 million
Result: reported results

Exact text from the filing

Total revenues were $17.4 million, driven primarily by $14.7 million in XDEMVY net product sales, representing approximately four months of sales following the launch in late August.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Tarsus Pharmaceuticals, Inc. reported Fourth Quarter 2023 results: revenue $13.1 million, net income $(41.9 million), EPS $(1.31).

Period: Fourth Quarter 2023
Revenue: $13.1 million
Net income: $(41.9 million)
EPS: $(1.31)
Result: reported results

Exact text from the filing

Recent Business Achievements Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four months since launch Delivered more than 17,400 bottles of XDEMVY to patients Continued pipeline execution – reported positive

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.